Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.
The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.
As numerous Car-T therapies battle it out in the burgeoning BCMA field, Ash shows that the real threat could come from elsewhere.
A recent technology deal with Notch points to a problem that all allogeneic cell therapy players might sooner or later have to tackle.
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.